Do patients followed in anticoagulation clinics for antiphospholipid syndrome meet criteria for the disorder?

Summary

Although specific criteria for diagnosing the antiphospholipid syndrome (APS) exist (the Sapporo Criteria), most physicians are not aware these include repeat testing and documentation of either a lupus anticoagulant or medium to high levels of anticardiolipin antibody. Incorrect diagnosis of APS may result in unnecessary long-term anticoagulation. The purpose of this study was to determine the clinical and serological characteristics of patients being treated for APS and concordance with published criteria. This cross-sectional study identified APS patients who were being treated with warfarin at one of three universitybased anticoagulation clinics. Levels of anticardiolipin antibody were classified as low-positive if abnormal but <40 GPL/MPL units and medium/high-positive if ≥40 units. Strength of meeting Sapporo criteria was graded as definite, possible, and not meeting criteria. Of 103 cases, 97 had clinical and laboratory data available. Only 10 cases (10%, 95% Confidence Interval 5 - 19) met criteria for definite APS, 16 (16%, 10 - 26) had a possible diagnosis, and 71 (73%, 63 - 81) did not meet criteria. Of 70 cases that had abnormal anticardiolipin antibody results, only 32 (46%, 34 - 58) had medium/high-positive levels. Repeat laboratory testing was performed in only 49 cases (51%, 40 - 61). We conclude that few patients treated forAPS met Sapporo criteria. Abnormal levels of anticardiolipin antibody were frequently in the low-positive range, and repeat testing was often absent. A quality improvement program that includes review of cases referred for chronic anticoagulation care is recommended to ensure appropriate testing and treatment of patients with suspected APS.

Keywords

Antiphospholipid antibody syndrome - lupus anticoagulant - anticardiolipin antibody - anticoagulation - diagnosis

• References

• 1 Manoussakis MN, Tzioufas AG, Silis MP. et al. High prevalence of anti-cardiolipin and other autoantibodies in a healthy elderly population.. Clin Exper Immunol 1987; 69: 557-65.
• 2 Petri M. Epidemiology of the antiphospholipid antibody syndrome.. J Autoimmunity 2000; 15: 145-51.
• 3 Thomas RH. Hypercoagulability syndromes.. Arch Intern Med 2001; 161: 2433-9.
• 4 Stegnar M, Bozic B, Peternel P. et al. Prevalence of antiphospholipid antibodies in deep vein thrombosis and their relationship to blood coagulation and fibrinolysis.. Thromb Res 1991; 63: 433-43.
• 5 Simioni P, Prandoni P, Zanon E. et al. Deep venous thrombosis and lupus anticoagulant. A case-control study.. Thromb Haemost 1996; 76: 187-9.
• 6 Wilson WA, Gharavi AE, Koike T. et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop.. Arthritis Rheum 1999; 42: 1309-11.
• 7 Crowther MA, Ginsberg JS, Julian J. et al. A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome.. N Engl J Med 2003; 349: 1133-8.
• 8 Levine JS, Branch DW, Rauch J. The antiphospholipid syndrome.. N Engl J Med 2002; 346: 752-63.
• 9 Harris EN, Chan JK, Asherson RA. et al. Thrombosis, recurrent fetal loss, and thrombocytopenia. Predictive value of the anticardiolipin antibody test.. Arch Intern Med 1986; 146: 2153-6.
• 10 Finazzi G. The Italian Registry of Antiphospholipid Antibodies.. Haematologica 1997; 82: 101-5.
• 11 Hyers TM, Agnelli G, Hull RD. et al. Antithrombotic therapy for venous thromboembolic disease.. Chest 2001; 119 (Suppl. 01) 176S-193S.
• 12 Lockshin MD. Antiphospholipid antibody. Babies, blood clots, biology.. JAMA 1997; 277: 1549-51.
• 13 Long AA, Ginsberg JS, Brill-Edwards P. et al. The relationship of antiphospholipid antibodies to thromboembolic disease in systemic lupus erythematosus: a cross-sectional study.. Thromb Haemost 1991; 66: 520-4.
• 14 Muir KW, Squire IB, Alwan W. et al. Anticardiolipin antibodies in an unselected stroke population.. Lancet 1994; 344: 452-6.
• 15 Mateo J, Oliver A, Borrell M. et al. Laboratory evaluation and clinical characteristics of 2,132 consecutive unselected patients with venous thromboembolism– results of the Spanish Multicentric Study on Thrombophilia (EMET-Study).. Thromb Haemost 1997; 77: 444-51.
• 16 Cabiedes J, Cabral AR, Alarcon-Segovia D. Clinical manifestations of the antiphospholipid syndrome in patients with systemic lupus erythematosus associate more strongly with anti-beta 2-glycoprotein-I than with antiphospholipid antibodies.. J Rheumatol 1995; 22: 1899-906.
• 17 Cervera R, Font J, Lopez-Soto A. et al. Isotype distribution of anticardiolipin antibodies in systemic lupus erythematosus: prospective analysis of a series of 100 patients.. Ann Rheum Dis 1990; 49: 109-13.
• 18 Italian Registry of Antiphospholipid Antibodies. Thrombosis and thrombocytopenia in antiphospholipid syndrome (idiopathic and secondary to SLE): first report from the Italian Registry.. Haematologica 1993; 78: 313-8.
• 19 The Antiphospholipid Antibodies in Stroke Study Group (APASS). Clinical, radiological, and pathological aspects of cerebrovascular disease associated with antiphospholipid antibodies.. Stroke 1993; 24 (Suppl. 12) I120-3.
• 20 Ginsberg JS, Wells PS, Brill-Edwards P. et al. Antiphospholipid antibodies and venous thromboembolism.. Blood 1995; 86: 3685-91.
• 21 Cabral AR, Cabiedes J, Alarcon-Segovia D. Antibodies to phospholipid-free beta 2-glycoprotein-I in patients with primary antiphospholipid syndrome.. J Rheumatol 1995; 22: 1894-8.
• 22 Finazzi G, Brancaccio V, Moia M. et al. Natural history and risk factors for thrombosis in 360 patients with antiphospholipid antibodies: a four-year prospective study from the Italian Registry.. Am J Med 1996; 100: 530-6.
• 23 Jouhikainen T. Detection of lupus anticoagulant by means of dilute Russell’s viper venom time is affected by oral anticoagulant therapy.. Blood Coagul Fibrinolysis 1990; 1: 627-32.
• 24 Lillicrap DP, Pinto M, Benford K. et al. Heterogeneity of laboratory test results for antiphospholipid antibodies in patients treated with chlorpromazine and other phenothiazines.. Am J Clin Pathol 1990; 93: 771-5.
• 25 Levy RA, Gharavi AE, Sammaritano LR. et al. Characteristics of IgG antiphospholipid antibodies in patients with systemic lupus erythematosus and syphilis.. J Rheumatol 1990; 17: 1036-41.
• 26 Canoso RT, Zon LI, Groopman JE. Anticardiolipin antibodies associated with HTLV-III infection.. Br J Haematol 1987; 65: 495-8.
• 27 Alarcon-Segovia D, Deleze M, Oria CV. et al. Antiphospholipid antibodies and the antiphospholipid syndrome in systemic lupus erythematosus. A prospective analysis of 500 consecutive patients.. Medicine 1989; 68: 353-65.